Literature DB >> 20623995

Clearance of HIV type 1 envelope recombinant sendai virus depends on CD4+ T cells and interferon-gamma but not B cells, CD8+ T cells, or perforin.

Sherri L Surman1, Scott A Brown, Bart G Jones, David L Woodland, Julia L Hurwitz.   

Abstract

T cell-mediated viral clearance is classically attributed to the CD8(+) T cell subset, but CD4(+) T cells can sometimes assume this role. One such instance was illustrated by the immunization of C57BL/6 mice with HIV-1 envelope, followed by challenge with a recombinant Sendai virus (rSeV-env) carrying a gene for secreted HIV-1 envelope protein. Vaccinated mice that lacked both B cells (microMT) and CD8(+) T cells controlled virus, but control was lost when CD4(+) T cells were depleted. To explain this activity, we questioned whether CD4(+) T cells might utilize perforin for killing of MHC class II-positive targets. We also asked if the process might depend on IFN-gamma, which can upregulate MHC expression and enhance T cell recruitment to sites of virus challenge. To address these possibilities, we vaccinated perforin-KO mice with HIV-1 envelope and challenged them with rSeV-env. We found that perforin was not required for (1) CD4(+) T cell homing to the site of virus challenge, (2) expression of Th1 and Th2 cytokines (including IFN-gamma), or (3) virus clearance. To determine if IFN-gamma was required for protection, we repeated experiments in IFN-gamma-KO animals. In this case, significant protection was lost, although the CD4(+) T cells trafficked readily to the site of infection. In fact, local CD4(+) T cell numbers in vaccinated IFN-gamma- KO mice exceeded those in wild type animals. In both cases, cells were alphass TCR(+), NK-1.1(-), and CD44(+), typifying an activated CD4(+) T cell subset. Taken together, our results showed that HIV-1 envelope recombinant virus clearance was dependent on CD4(+) T cells and IFN-gamma, but occurred in the absence of B cells, CD8(+) T cells, or perforin.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20623995      PMCID: PMC2932556          DOI: 10.1089/aid.2009.0266

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  55 in total

1.  Localization of CD4+ T cell epitope hotspots to exposed strands of HIV envelope glycoprotein suggests structural influences on antigen processing.

Authors:  S Surman; T D Lockey; K S Slobod; B Jones; J M Riberdy; S W White; P C Doherty; J L Hurwitz
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-03       Impact factor: 11.205

Review 2.  Protection from HIV/AIDS: the importance of innate immunity.

Authors:  Jay A Levy; Iain Scott; Carl Mackewicz
Journal:  Clin Immunol       Date:  2003-09       Impact factor: 3.969

3.  IFN-gamma reverses the stop signal allowing migration of antigen-specific T cells into inflammatory sites.

Authors:  Szun S Tay; Ann McCormack; Charlotte Lawson; Marlene L Rose
Journal:  J Immunol       Date:  2003-03-15       Impact factor: 5.422

4.  Antibody-independent antiviral function of memory CD4+ T cells in vivo requires regulatory signals from CD8+ effector T cells.

Authors:  W Zhong; A D Roberts; D L Woodland
Journal:  J Immunol       Date:  2001-08-01       Impact factor: 5.422

5.  Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques.

Authors:  I M Belyakov; Z Hel; B Kelsall; V A Kuznetsov; J D Ahlers; J Nacsa; D I Watkins; T M Allen; A Sette; J Altman; R Woodward; P D Markham; J D Clements; G Franchini; W Strober; J A Berzofsky
Journal:  Nat Med       Date:  2001-12       Impact factor: 53.440

Review 6.  Reactive oxygen and reactive nitrogen intermediates in innate and specific immunity.

Authors:  C Bogdan; M Röllinghoff; A Diefenbach
Journal:  Curr Opin Immunol       Date:  2000-02       Impact factor: 7.486

7.  Characterization of CD4(+) CTLs ex vivo.

Authors:  Victor Appay; John J Zaunders; Laura Papagno; Julian Sutton; Angel Jaramillo; Anele Waters; Philippa Easterbrook; Pat Grey; Don Smith; Andrew J McMichael; David A Cooper; Sarah L Rowland-Jones; Anthony D Kelleher
Journal:  J Immunol       Date:  2002-06-01       Impact factor: 5.422

8.  Virus clearance and immunopathology by CD8(+) T cells during infection with respiratory syncytial virus are mediated by IFN-gamma.

Authors:  Tobias Ostler; Wendy Davidson; Stephan Ehl
Journal:  Eur J Immunol       Date:  2002-08       Impact factor: 5.532

9.  A recombinant Sendai virus is controlled by CD4+ effector T cells responding to a secreted human immunodeficiency virus type 1 envelope glycoprotein.

Authors:  Scott A Brown; Julia L Hurwitz; Amy Zirkel; Sherri Surman; Toru Takimoto; Irina Alymova; Chris Coleclough; Allen Portner; Peter C Doherty; Karen S Slobod
Journal:  J Virol       Date:  2007-07-25       Impact factor: 5.103

10.  Clustering of Th cell epitopes on exposed regions of HIV envelope despite defects in antibody activity.

Authors:  Scott A Brown; John Stambas; Xiaoyan Zhan; Karen S Slobod; Chris Coleclough; Amy Zirkel; Sherri Surman; Stephen W White; Peter C Doherty; Julia L Hurwitz
Journal:  J Immunol       Date:  2003-10-15       Impact factor: 5.422

View more
  4 in total

1.  UV-inactivated vaccinia virus (VV) in a multi-envelope DNA-VV-protein (DVP) HIV-1 vaccine protects macaques from lethal challenge with heterologous SHIV.

Authors:  Bart G Jones; Robert E Sealy; Xiaoyan Zhan; Pamela J Freiden; Sherri L Surman; James L Blanchard; Julia L Hurwitz
Journal:  Vaccine       Date:  2012-03-14       Impact factor: 3.641

Review 2.  Respiratory syncytial virus vaccine development.

Authors:  Julia L Hurwitz
Journal:  Expert Rev Vaccines       Date:  2011-10       Impact factor: 5.217

3.  Differential localization and function of antibody-forming cells responsive to inactivated or live-attenuated influenza virus vaccines.

Authors:  Robert Sealy; Richard J Webby; Jeri C Crumpton; Julia L Hurwitz
Journal:  Int Immunol       Date:  2012-11-08       Impact factor: 4.823

4.  CD4+ T cells support establishment of RSV-specific IgG and IgA antibody secreting cells in the upper and lower murine respiratory tract following RSV infection.

Authors:  Robert E Sealy; Sherri L Surman; Julia L Hurwitz
Journal:  Vaccine       Date:  2017-04-11       Impact factor: 3.641

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.